JonesTrading analyst Justin Walsh has maintained their bullish stance on RAPP stock, giving a Buy rating on August 11.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Justin Walsh has given his Buy rating due to a combination of factors that highlight the potential of Rapport Therapeutics, Inc. The company’s RAP technology is expected to be both clinically effective and commercially competitive across multiple central nervous system (CNS) indications. This is particularly significant as the company prepares for a topline data readout in September 2025 for RAP-219 in refractory focal epilepsy, which could provide early clinical validation and boost interest in the company.
Furthermore, the strategic focus on RAPs and the use of biomarker-informed trial designs are anticipated to create a robust pipeline that could drive long-term value for shareholders. The upcoming events, including a webcast and dinner with key opinion leaders in the field of epilepsy, underscore the company’s commitment to advancing its position in the epilepsy treatment landscape. These factors collectively contribute to the positive outlook and the Buy rating for Rapport Therapeutics, Inc.
In another report released on August 11, H.C. Wainwright also reiterated a Buy rating on the stock with a $31.00 price target.
RAPP’s price has also changed slightly for the past six months – from $13.670 to $14.240, which is a 4.17% increase.